ViewRay, Inc. (VRAYQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.34: the stock has moved about 34% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerViewRay, Inc. (VRAYQ) trades at $0.0001. ViewRay, Inc. is a healthcare company specializing in MRI-guided radiation therapy systems for cancer treatment. Founded in 2004, it has faced significant challenges, including a recent bankruptcy filing. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for VRAYQ: VRAYQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ViewRay, Inc. (VRAYQ) Healthcare & Pipeline Overview
ViewRay, Inc. is a pioneering healthcare company focused on MRI-guided radiation therapy systems, addressing critical challenges in cancer treatment with innovative technology and a global reach in key markets.
What Is the Investment Thesis for VRAYQ?
ViewRay, Inc. is currently navigating a challenging financial landscape following its Chapter 11 bankruptcy filing, which has since transitioned to Chapter 7. The company’s innovative MRIdian system represents a significant advancement in cancer treatment technology, addressing critical issues in radiation therapy. However, with a profit margin of -105.2% and a gross margin of only 9.8%, the company faces substantial operational hurdles. The competitive landscape includes established players in the medical devices sector, making it imperative for ViewRay to either find a path to recovery or face potential liquidation. The future of ViewRay hinges on its ability to either restructure effectively or attract new investment to revive its operations, particularly in light of the growing demand for advanced cancer treatment technologies, projected to expand at a CAGR of 7.5% through 2030.
Based on FMP financials and quantitative analysis
VRAYQ Key Highlights
Market Cap: $0.00B, indicating significant financial distress and recent bankruptcy.
- Profit Margin: -105.2%, reflecting ongoing operational losses.
- Gross Margin: 9.8%, which is below industry standards, highlighting efficiency challenges.
- Beta: 1.34, indicating higher volatility compared to the market.
- Dividend Yield: None, as the company does not currently return capital to shareholders.
Who Are VRAYQ's Competitors?
VRAYQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| VAR VAR | $177.07 | 0.00% | — | |
| CIVI Civitas Resources, Inc. | $27.38 | -1.37% | $2.34B | — |
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | — | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | — |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | — |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | — |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRAYQ's Key Strengths?
Innovative MRIdian technology that enhances treatment precision.
- Established presence in multiple international markets.
- Strong network of healthcare providers and institutions.
What Are VRAYQ's Weaknesses?
Recent bankruptcy filing raises concerns about financial stability.
- Low gross margins indicate potential operational inefficiencies.
- Dependence on a limited product line for revenue generation.
What Are the Key Risks for VRAYQ?
Financial-distress signal — its Altman Z-Score of -6.12 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-85.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
- Ongoing financial instability and uncertainty following bankruptcy.
- Intense competition from established players in the medical devices sector.
- Regulatory challenges in various international markets affecting product sales.
What Threats Does VRAYQ Face?
- Intense competition from established medical device companies.
- Regulatory challenges in different international markets.
- Market volatility and economic downturns affecting healthcare spending.
What Are VRAYQ's Competitive Advantages?
- Innovative technology that combines MRI imaging with radiation therapy.
- Strong intellectual property portfolio protecting proprietary technology.
- Established relationships with key healthcare providers and institutions.
- Specialization in a niche market of MRI-guided radiation therapy.
- Potential for improved patient outcomes, enhancing customer loyalty.
What Does VRAYQ Do?
Founded in 2004 and headquartered in Denver, Colorado, ViewRay, Inc. designs, manufactures, and markets advanced magnetic resonance imaging (MRI) guided radiation therapy systems, primarily aimed at treating cancer patients. The company's flagship product, MRIdian, utilizes MRI technology to provide real-time imaging during radiation therapy, which helps mitigate issues such as beam distortion and skin toxicity, thereby enhancing treatment precision and patient outcomes. ViewRay serves a diverse clientele that includes university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers across the United States, Italy, France, Taiwan, the United Kingdom, and other international markets. Despite its innovative offerings, ViewRay has faced significant challenges, culminating in a voluntary petition for reorganization under Chapter 11 bankruptcy in July 2023, which was later converted to Chapter 7 in October 2023, indicating a critical juncture in the company's operational viability. The company has built a network of direct sales forces and distributors to effectively reach its target markets, positioning itself as a leader in the niche of MRI-guided radiation therapy. However, the recent financial difficulties raise questions about its future operational capabilities and market presence.
What Products and Services Does VRAYQ Offer?
- Design and manufacture MRI-guided radiation therapy systems.
- Market the MRIdian system for cancer treatment.
- Address beam distortion and skin toxicity in radiation therapy.
- Serve a diverse range of healthcare institutions globally.
- Utilize a network of direct sales and distributors.
- Focus on enhancing treatment precision and patient outcomes.
How Does VRAYQ Make Money?
- Revenue generated from the sale of MRI-guided radiation therapy systems.
- Ongoing service and maintenance contracts for installed systems.
- Potential revenue from partnerships and collaborations in clinical research.
- Sales through a combination of direct sales force and distribution networks.
- Focus on high-value contracts with hospitals and cancer treatment centers.
What Industry Does VRAYQ Operate In?
The medical devices industry is experiencing robust growth, driven by technological advancements and increasing demand for innovative healthcare solutions. The global market for cancer treatment technologies is projected to grow at a CAGR of 7.5%, reaching approximately $200 billion by 2030. ViewRay, Inc. operates in a competitive landscape that includes both established players and emerging companies focused on radiation therapy solutions. The shift towards personalized medicine and advanced imaging technologies positions ViewRay as a key player, although its recent financial challenges may hinder its ability to capitalize on these market trends.
Who Are VRAYQ's Key Customers?
- University research and teaching hospitals.
- Community hospitals and private practices.
- Government institutions and healthcare systems.
- Freestanding cancer centers.
- International markets including Europe and Asia.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
ViewRay, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.12 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for ViewRay, Inc. stands at -85.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.5%, showing how much profit it generates from its asset base. A current ratio of 2.36 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
ViewRay, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Oakwood Village, US. VRAYQ has traded publicly since 2015.
Earnings Track Record
ViewRay, Inc. has missed Wall Street's EPS estimate in 2 of its last 4 reported quarters — a mixed record worth weighing. Reported results have landed about 1.2% below estimates on average.
Forward Outlook
Wall Street analysts project ViewRay, Inc. revenue of about $306.4M for fiscal 2026, with EPS near $-0.06.
VRAYQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VRAYQ Latest News
No recent news available for VRAYQ.
VRAYQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VRAYQ.
Price Targets
Wall Street price target analysis for VRAYQ.
VRAYQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VRAYQ; grades run from A+ (80-100) to F (below 30).
Leadership: Paul Ziegler Jr.
CEO
Paul Ziegler Jr. has extensive experience in the healthcare sector, particularly in medical devices. He has held various leadership roles in companies focused on innovative healthcare solutions, bringing a wealth of knowledge in management and operational strategy. Ziegler holds a degree in engineering and has a strong background in product development and commercialization.
Track Record: Under Ziegler's leadership, ViewRay has developed its MRIdian technology and expanded its market presence, although recent financial challenges have posed significant hurdles. His strategic focus on innovation and partnerships has been critical in positioning the company within the competitive landscape of cancer treatment technologies.
VRAYQ OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements and lower visibility in the market, which can affect liquidity and investor confidence.
- OTC Tier: OTC Other
- Limited financial reporting and transparency due to bankruptcy proceedings.
- Potential for significant price volatility given the company's financial distress.
- Lower investor confidence in OTC stocks compared to those on major exchanges.
- Review recent financial statements and bankruptcy filings.
- Assess the company's market position and competitive landscape.
- Evaluate management's track record and strategic plans for recovery.
- Investigate any ongoing litigation or regulatory issues.
- Confirm the company's ability to continue operations post-bankruptcy.
- Established history since 2004 in the medical device sector.
- Innovative technology with potential applications in cancer treatment.
- Partnerships with recognized healthcare institutions and research organizations.
What Investors Ask About ViewRay, Inc. (VRAYQ) — Healthcare
What revenue streams does ViewRay, Inc. have in healthcare?
ViewRay generates revenue primarily through the sale of its MRI-guided radiation therapy systems, particularly the MRIdian system. Additionally, the company earns income from ongoing service and maintenance contracts for installed systems.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Company is currently in bankruptcy proceedings, impacting financial transparency.